Candriam Luxembourg S.C.A. Acquires 105,838 Shares of Epizyme Inc (NASDAQ:EPZM)

Candriam Luxembourg S.C.A. raised its holdings in Epizyme Inc (NASDAQ:EPZM) by 94.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 217,338 shares of the biopharmaceutical company’s stock after purchasing an additional 105,838 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Epizyme were worth $5,347,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of EPZM. FMR LLC raised its position in shares of Epizyme by 0.3% during the first quarter. FMR LLC now owns 3,484,137 shares of the biopharmaceutical company’s stock worth $43,169,000 after acquiring an additional 11,759 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of Epizyme by 14.5% during the fourth quarter. Victory Capital Management Inc. now owns 2,490,092 shares of the biopharmaceutical company’s stock worth $52,117,000 after acquiring an additional 314,404 shares during the last quarter. Voya Investment Management LLC raised its position in shares of Epizyme by 133.3% during the third quarter. Voya Investment Management LLC now owns 651,683 shares of the biopharmaceutical company’s stock worth $6,722,000 after acquiring an additional 372,321 shares during the last quarter. Nuveen Asset Management LLC bought a new stake in shares of Epizyme during the second quarter worth $3,960,000. Finally, California Public Employees Retirement System raised its position in shares of Epizyme by 17.4% during the third quarter. California Public Employees Retirement System now owns 270,445 shares of the biopharmaceutical company’s stock worth $2,790,000 after acquiring an additional 40,055 shares during the last quarter. Hedge funds and other institutional investors own 87.02% of the company’s stock.

EPZM has been the subject of a number of recent research reports. Zacks Investment Research downgraded Epizyme from a “hold” rating to a “sell” rating and set a $11.00 target price for the company. in a research report on Monday, October 21st. Cowen boosted their target price on Epizyme from $18.00 to $36.00 and gave the stock an “outperform” rating in a research report on Friday, January 24th. Svb Leerink downgraded Epizyme from an “outperform” rating to a “market perform” rating in a research report on Friday, January 24th. HC Wainwright restated a “buy” rating on shares of Epizyme in a research report on Thursday, October 31st. Finally, Wedbush boosted their target price on Epizyme from $24.00 to $30.00 and gave the stock an “outperform” rating in a research report on Friday, January 24th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $25.13.

NASDAQ EPZM opened at $24.26 on Friday. The stock has a 50-day simple moving average of $23.48 and a 200 day simple moving average of $16.07. The company has a current ratio of 10.90, a quick ratio of 10.90 and a debt-to-equity ratio of 0.03. Epizyme Inc has a 12 month low of $9.73 and a 12 month high of $27.82.

In related news, insider Shefali Agarwal sold 1,843 shares of the company’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $24.64, for a total value of $45,411.52. Following the completion of the sale, the insider now owns 63,276 shares in the company, valued at $1,559,120.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert B. Bazemore sold 6,074 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $20.44, for a total value of $124,152.56. Following the completion of the sale, the chief executive officer now owns 93,744 shares of the company’s stock, valued at approximately $1,916,127.36. The disclosure for this sale can be found here. Insiders sold 13,549 shares of company stock valued at $297,231 in the last quarter. 16.60% of the stock is currently owned by corporate insiders.

About Epizyme

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

See Also: How to Invest in an Index Fund

Want to see what other hedge funds are holding EPZM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Epizyme Inc (NASDAQ:EPZM).

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.